Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
NCT05530421
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This research wants to find out if using a combination of three medicines called selinexor, venetoclax, and dexamethasone can make cancer treatment better for people with a type of cancer called translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM). They want to see if these medicines can help more than just one medicine alone.
This research wants to find out if using a combination of three medicines called selinexor, venetoclax, and dexamethasone can make cancer treatment better for people with a type of cancer called translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM). They want to see if these medicines can help more than just one medicine alone.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).
The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
